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Erythropoietin (EPO) is a heavily glycosylated hormone whose recombinant forms are used for 
treatment of anaemia. EPO glycosylation is important for its pharmacological properties. An analytical 
workflow, which can determine EPO glycosylation in an accurate and high-throughput fashion 
from cell culture supernatant (CCS) in approximately 24 h, offers the possibility to follow changes 
during production. To address this challenge, we present a complete workflow consisting of protein 
purification, glycan release, sialic acid derivatization, solid phase extraction, matrix-assisted laser 
desorption/ionization - mass spectrometry (MALDI-MS) analysis and MassyTools data processing. EPO 
purification from CCS by anti-EPO antibody coupled Sepharose beads yielded excellent purity with 
acceptable recovery and was free of glycoform bias. Glycosylation profiles obtained by MALDI-MS were 
highly comparable to those obtained with an established capillary gel electrophoresis–laser induced 
fluorescence method. Our method delivers accurate results for the analysis of changes of important 
glycosylation parameters, such as sialylation and number of N-acetyllactosamine units, for the time 
course of a fermentation. We could resolve differences in glycosylation between several CCS samples.
Erythropoietin (EPO) is a glycoprotein hormone best known for its role in the production of red blood cells, 
though it has multiple other physiological functions1. Its stimulation of erythropoiesis is therapeutically exploited, 
for example in the treatment of anaemia in chronic kidney disease and cancer2, 3. Consequently, recombinant 
human EPO is an important biopharmaceutical drug. Four forms, namely epoetin alfa, epoetin beta, epoetin delta 
and darbepoetin alfa, are distinguished mainly by their glycosylation (for example, in darbepoetin alfa, five amino 
acids are changed to generate two additional glycosylation sites)4–6. This and the fact that approximately half of 
EPO molecular weight is due to the glycan content, underlines the importance of glycan analysis for therapeutic 
EPO.
Typical glycan structures found on EPO’s three (epoetin) or five (darbepoetin) N-glycosylation sites are com-
plex and mainly composed of tri- and tetra-antennary glycan structures with near complete galactosylation and 
high degrees of sialylation. Due to the faster clearance of galactose-terminated and low-antennary structures, 
sialic acid content and antennary structure represent critical quality attributes4. Additionally, distinction of 
N-acetylneuraminic acid (NeuAc) and N-glycolylneuraminic acid (NeuGc), the number of N-acetyllactosamine 
(LacNAc) repeats and the degree of O-acetylation (Ac) of sialic acids are relevant for pharmacokinetics4.
Although analytical release testing of biopharmaceuticals is performed on drug substances, which undergo 
multiple purification steps unrelated to the analysis, many discovery and development tasks require purifica-
tion from cell culture supernatant (CCS). The possibility to analyze fermenter time course samples also opens 
new opportunities for biotechnological processes. For this purpose, elaborate glycoprotein purification schemes, 
such as multiple sequential chromatographic purifications, are too time consuming for fast analytical testing7. 
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Moreover, considering the complexity of EPO, some extreme proteoforms may be lost by applying multiple sam-
ple purification steps. Affinity purification of EPO may represent a faster and more inclusive alternative. Several 
methods are available, varying in affinity partners and formats8. Mainly, anti-EPO antibodies are used as affinity 
partners, but others have been applied such as synthetic peptides, lectins and the erythropoietin receptor8, 9. 
Concerning formats, immobilization of the affinity partner to (monolithic) columns, well plates, magnetic and 
Sepharose beads have been reported8. Alternatively, recombinant EPO with a poly-histidine tag or expressed as a 
fusion protein, can be used for EPO purification from complex matrices10, 11. The large majority of characteriza-
tion studies were done on EPO purified from human or animal body fluids whereas studies of recombinant EPO, 
purified from CCS, are rare8, 12, 13. To our best knowledge, no MS compatible purification strategy has demon-
strated equivalence of the glycoform distribution before and after purification14.
Several methods for glycosylation analysis of purified EPO are available which have been recently reviewed4, 15, 16. 
Analysis of PNGaseF-released N-glycans is one of the most common approaches, though it does not address 
the site-specific microheterogeneity and completely ignores O-glycosylation. Among the approaches for 
released N-glycan detection, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS) is frequently used, due to its high throughput (HT) and high information content. Though 
some reports have introduced reducing end derivatization in order to allow additional analysis by liquid chro-
matography with fluorescence detection (LC-FLD)17, 18, MALDI-MS analysis of non-derivatized glycans omits 
the intrinsic bias and reduced accuracy associated with this additional sample preparation step19, 20. However, 
derivatization of sialic acids can be useful to neutralize the charge and reduce the known instability of sialic 
acid containing glycans, observed in the reflectron mode of time-of-flight mass detection21. This phenomenon is 
often circumvented by desialylation prior to MALDI-MS and parallel analysis of sialylation by complementary 
techniques17. Another alternative is permethylation, but this derivatization technique suffers from the presence 
of satellite peaks, mainly due to incomplete or unwanted additional methylation22. All MALDI-MS methods for 
EPO glycosylation analysis described in literature report quite extensive sample preparation protocols, often fea-
turing separate steps for desalting, protein removal, removal of excess label and even fractionation either by anion 
exchange or normal phase (liquid chromatography) LC7, 17–19.
Here, we report an HT workflow for EPO glycosylation analysis consisting of (1) EPO affinity purification, 
based on Sepharose bead-linked anti-EPO antibodies, from CCS, (2) efficiently stabilizing and easily interpretable 
sialic acid derivatization, (3) straightforward and easily automatable sample preparation, (4) high sensitivity and 
high resolution MALDI-TOF-MS analysis and (5) automated data processing (see Fig. 1). This approach could 
be used for analysis of recombinant EPO glycosylation. We envision that the method can provide fast feedback 
during discovery and development, especially where regular purification schemes are complex or not yet devel-
oped. Additionally, our method presents an alternative analysis pathway which may be able to pinpoint whether 
changes observed in the drug substance arise from changes in production or deviations in purification.
Materials and Methods
Samples and chemicals. Sepharose beads coupled to anti-erythropoetin antibodies (beads), erythropoetin 
reference standard (EPO standard) and CCS containing erythropoetin were kindly provided by Hoffmann-La 
Roche (Roche Diagnostics, Penzberg, Germany). Polyclonal antibodies from sheep raw serum were purified by 
delipidation, ammonium sulfate precipitation and ion exchange chromatography. The resulting antibodies were 
partially purified by immunoaffinity chromatography using EPO-sepharose. 10 mg of purified anti-erythrope-
tin-antibodies were than coupled to 1 ml of NHS-activated Sepharose 4 Fast flow Beads following the instructions 
manual 71-5000-14 AD (GE Healthcare Life Sciences, Chicago, USA). The erythropoietin producing Chinese 
hamster ovary cell line was cultivated in chemically defined, animal component-free growth media. Samples were 
taken daily. The CCS sample was stored at −20 °C for later analysis. The 10 CCS samples, that were compared, 
were sampled at different time points from the same fermenter run. Beads were stored as a slurry containing 
60% (v/v) of a mixture of phosphate-buffered saline (PBS) with 0.1% sodium azide (bead buffer). Furthermore, 
Figure 1. The CCS was mixed and incubated with anti-EPO beads in a 96-well filter plate. After washing, pure 
proteins were eluted in HCl and freeze dried. Glycans were prepared by PNGaseF release without additional 
denaturation, lactonization for stabilization and HILIC-SPE. MALDI-TOF-MS analysis in reflectron positive 
mode yielded high quality spectra which were automatically quantified with MassyTools.
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Peptide-N-glycosidase F (PNGaseF) was bought at Roche Diagnostics (Mannheim, Germany). 1-ethyl-3-(3-(di-
methylaminopropyl)carbodiimide hydrochloride (EDC) was purchased from Fluorochem (Hadfield, United 
Kingdom). The following solvents and acids were from Merck KGaA (Darmstadt, Germany) and of analyti-
cal grade: ethanol, trifluoroacetic acid (TFA) and hydrochloric acid (HCl). Acetonitrile (ACN) was ordered at 
Biosolve (Valkenswaard, The Netherlands). Deionized water was generated with a Purelab ultra (ELGA Labwater, 
Ede, The Netherlands). All other chemicals were acquired in at least analytical quality from Sigma-Aldrich 
(Steinheim, Germany).
Affinity purification. 40 µL beads (100 µL slurry) were mixed with the sample in a 96-well filter plate 
(0.65 µm hydrophilic low protein binding Durapore membrane, Merck KGaA, Darmstadt, Germany). 5 µg EPO 
were applied unless otherwise stated, amounting to 180 µL of CCS or 2.5 µL of the EPO standard. Incubation at 
room temperature for an hour on a shaker ensured interaction between EPO and the antibodies. After capturing, 
the supernatant was eluted and the beads were washed three times with PBS and three times with water by centrif-
ugation at 50 g. Elution was achieved by applying twice 100 µL 100 mM HCl which was eluted each at 500 g after 
5 min vigorous shaking. The eluates were evaporated to dryness by freeze-drying in a centrifugal vacuum concen-
trator set to 60 °C (RVC2–25COplus, Martin Christ Gefriertrocknungsanlagen, Osterode am Harz, Germany).
To assess the purity and estimate recovery, the purification was done in triplicate and compared by sodium 
dodecylsulfate - polyacrylamide gel electrophoresis (SDS-PAGE) to a negative control (blank; no EPO added to 
the purification) and 1 µg, 2 µg and 5 µg of the EPO standard. For molecular weight determination a Novex Sharp 
Pre-Stained Protein Standard (Life Technologies, Paisley, UK) was taken along. SDS-PAGE was performed on a 
NuPage 4–12% Bis-Tris SDS-PAGE gel in MES SDS running buffer (both Life Technologies) after reduction for 
10 min at 100 °C in Laemmli buffer with 1.3% β-mercaptoethanol23. Staining was achieved with Coommassie 
G-250 SimplyBlue SafeStain (Life Technologies).
Recovery was mainly assessed by a bicinchoninic acid (BCA) assay24. A micro BCA™ protein assay kit 
(ThermoFischer Scientific, Rockford, IL, USA) was used according to supplier specifications with one exception: 
the EPO standard was used for the calibration curve instead of bovine serum albumin.
PNGaseF digestion. Freeze-dried eluates were reconstituted in 10 µL of a PBS solution containing 1% 
NP-40 and 0.5 U PNGaseF. After careful shaking for 10 min at room temperature, glycan release was achieved by 
incubating for 18 h at 37 °C.
In cases where the affinity purification was not performed, e.g. where the EPO standard was directly analysed, 
denaturation was achieved by incubation in 100 mM HCl or FA for 15 min at room temperature and subsequent 
freeze-drying (as described above). At least 75% (v/v) of the acid solution should be added to the sample and 
in strongly buffered samples the pH should be checked to be around or below 3. For immunoglobulin G gly-
cosylation analysis, it has already been shown that acid denaturation is equally efficient as urea denaturation, 
reduction and alkylation23. Therefore, we investigated whether the dedicated detergent-assisted heat denaturing 
step, often employed in literature, was necessary for our analysis. We used a protocol in which the dried eluates 
from affinity purification were reconstituted in 5 µL 2% SDS for 5 min by vigorous shaking21. Afterwards, samples 
were incubated for 10 min at 60 °C. After cooling to room temperature, an equal volume of the NP-40/PGNaseF 
mixture was added and glycan release protocol continued as described above (notwithstanding protein:enzyme 
ratio changes).
Derivatization, glycan enrichment and mass spectrometric analysis. Sialic acids were derivat-
ized by ethyl esterification similarly to a previously described protocol21. In short, 100 µL of ethanol containing 
250 mM each of EDC and 1-hydroxybenzotriazole hydrate were added for protein precipitation and derivatiza-
tion. After incubation at 37 °C for one hour, 110 µL of ACN were added. From this solution, released and derivat-
ized glycans were captured with in-house prepared hydrophilic interaction liquid chromatography – solid phase 
extraction (HILIC-SPE) pipet tips21. In brief, the pipet tips filled with a cotton thread were washed three times 
with 20 µL water and equilibrated three times with 20 µL of 85% aqueous ACN. After capture by 20 times filling 
and emptying, the pipet tips were washed three times each with 20 µL of 85% aqueous ACN with and without 1% 
TFA. Finally, glycans were eluted in 10 µL water.
The MALDI-TOF-MS experiments were conducted with the same instrumentation and settings as reported 
earlier20. Samples were prepared by mixing 4 µL of sample with 1 µL of matrix on a MALDI target plate 
800/384 MTP AnchorChip (Bruker Daltonics, Bremen, Germany). The matrix consisted of a 9:1 mixture of 
2,5-dihydroxybenzoic acid and 2-hydroxy-5-methoxybenzoic acid, sold as superDHB, and was dissolved at 
5 mg/mL in 50% aqueous ACN containing 1 mM sodium hydroxide. Spectra were acquired on an ultrafleXtreme 
(Bruker Daltonics) between m/z 1000 and m/z 5000 in reflectron positive mode. Acceleration voltage was set to 
25 kV and extraction delay to 140 ns. Spectra were accumulated with 20000 laser shots at 1000 Hz using a random 
walk algorithm and 200 shots per raster spot.
Data analysis. The highest quality spectrum of the EPO standard and the EPO purified from CCS each was 
manually inspected for signals. These were assigned tentative compositions and glycoforms based on accurate 
mass measurements and known EPO glycosylation4. From these tentative compositions a calibration list and an 
analyte list were generated to be used in automated data (pre-)processing by MassyTools (version 1.8.1.2)25. With 
the help of this program, the spectra were internally calibrated and background corrected relative abundances of 
the analytes were extracted. Based on analyte quality criteria, analytes were selected for inclusion in the final rel-
ative quantitation. Analytes (1) had to be above a signal-to-noise (S/N) of 9 in at least 11 of 12 measurements, (2) 
have an average mass error of between −10 ppm and 10 ppm, (3) show an average isotopic pattern quality (IPQ) 
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score ≤0.10 and (4) contribute ≥0.20% to the initial profile (equivalent to ca. ≥0.25% after analyte curation) to 
be considered for quantitation.
Capillary gel electrophoresis – laser induced fluorescence. Unlabelled released glycans of the EPO 
standard were prepared in the same fashion as described above, except that they were additionally desialylated 
by sialidase treatment in parallel to the glycan release. Desialylated glycans were detected by capillary gel electro-
phoresis – laser induced fluorescence (CGE–LIF) as described earlier26. In brief, dried glycans were labelled with 
8-aminopyrene-1,3,6-trisulfonic acid (ATPS) and purified by SPE. After addition of a size standard, samples were 
run on a DNA analyser (3730 DNA Analyzer, Applied Biosystems, Thermo Fisher Scientific).
Results and Discussion
In this study, we developed a workflow for the accurate relative quantitation of EPO N-glycans directly isolated 
from cell culture supernatant. The analysis of released N-glycans by MALDI-TOF-MS is based on a recently intro-
duced protocol which requires relatively few hands-on steps and is additionally very suitable for multiplexing 
and automation21, 27. MALDI-TOF-MS spectra of an EPO standard and EPO purified from CCS (see Fig. 1 and 
Material and Methods) are displayed in Fig. 2.
Structure assignment. The 9 most abundant compositions in both the EPO standard and the purified 
EPO from CCS contained 2 to 6 LacNAc units, between 2 and 4 α2,3-linked sialic acids and were singly fuco-
sylated. Individual glycoforms of these compositions arose from the decoration with between 0 and 3 sialic acid 
O-acetylations. In the following, we use compositions where O-acetylation variants are summed and glycoforms 
where individual O-acetylation variants are considered. The majority of sialic acids were N-acetylneuraminic 
acids (NANA), but many major compositions also showed a form where one NANA was replaced with an 
N-glycolylneuraminic acid (NGNA). Minor species included phosphorylated high mannose type glycans and 
compositions with equal amounts of hexoses and N-acetylhexoses. Accurate mass determination also suggest 
compositions with two or no fucose residues or more sialic acids than antennae. A complete overview of gly-
coforms confirmed in the assay performance experiments is listed in the Supporting Information Table S1. 
Additionally, a limited characterization has been performed on the EPO standard and the CCS EPO and is pre-
sented in a separate section at the end of the Supporting Information.
Figure 2. Representative MALDI-TOF-MS spectra of EPO N-glycans. (A) A spectrum of the EPO standard. 
It should be noted that the antenna isomerism indicated for the partially sialylated tri-antennary glycan also 
applies to all other tri-antennary structures. In addition, there may be minor contributions of bi-antennary 
structures with one LacNAc repeat. The tetra-antennary glycans have significant contributions of tri-antennary 
structures with one additional LacNAc repeat, as exemplified for the glycan with two NANA and 4 LacNAc 
units. (B) The major N-glycans detected for EPO purified from CCS were very similar to those of the EPO 
standard albeit in different relative abundances. 2× and 3× gives the incidence of the monosaccharide or 
antenna to the right or below. The brackets signify that the exact positions of substituents are unclear. The N-
acetylneuraminic acids to the right of the vertical brackets may cap an antenna or LacNAc-repeat.
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Several low abundant EPO glycosylation variants observed in the CCS material were not detectable or quanti-
fiable in the bio-processed EPO standard. In detail, the phosphorylated high mannose glycans, the di-fucosylated 
structures and compositions with higher sialic acid numbers then antennae (except H6N5F1S4) were not ver-
ified in the EPO standard (see Supporting Information Table S1). Overall, the data suggests that more com-
plex EPO glycan structures with higher mannose/sialic acid content are removed by the currently applied 
bio-pharmaceutical purification process.
Since minor changes in the analyte profile are expected during method optimization, especially with respect to 
changing sensitivity, it is not meaningful to use the complete analyte list for optimization experiments. Therefore, 
these were analysed using the 9 most abundant compositions and the most abundant phosphorylated high man-
nose glycan (Man6P; see Supporting Information Table S2). As O-acetylation of sialic acids was hard to quantify 
reliably, these peaks/glycoforms as well as salt adducts (for the high mannose glycans) are summed into a single 
value and reported as compositions.
With regard to the LacNAc units, literature reports the presence of mainly tri- and tetra-antennary gly-
cans with lower abundance of bi-antennary glycans. LacNAc repeats are also well established, but limited to 
tri- and tetra-antennary glycans4, 28. Linkage isomerism with respect to the antennae is limited to tri-antennary 
glycans, having two antennae either on the α1,3- or α1,6-mannose, as all galactoses are linked in a β1–4 fash-
ion28. Localization of one or multiple LacNAc repeats to different antennae potentially produces another form of 
isomerism. Complete fucosylation is reported and has been identified as α1,6-linked core fucose17, 28. It is well 
known that CHO cells usually produce exclusively α2,3-linked sialic acids. Sialic acids on EPO are known to carry 
O-acetylations and NGNA content and incomplete antenna sialylation are likewise established4, 17, 28. More sialic 
acids than antennae are also documented for EPO29. Phosphorylated high mannose type glycans are known to be 
present in minor quantities4. Afucosylated EPO glycans have been reported to be synthesized in CHO cells under 
specific conditions, so their detection at low abundance is not surprising30. To our best knowledge, the existence 
of glycans with equal amounts of hexoses and N-acetylhexosamines and of difucosylated glycans has not been 
reported so far.
Affinity purification. The initial step of the sample preparation is key in ensuring that detected glycans 
derive predominantly from EPO and not from other glycoproteins present in the CCS. To this end, we used 
anti-EPO antibodies coupled to Sepharose beads for trapping and washing on a filter plate. Selectivity and recov-
ery are crucial parameters.
Selectivity. SDS-PAGE was employed to verify the purity of EPO after affinity purification from CCS (see Fig. 3). 
The EPO standard migrates close to the 37 kDa marker protein. The non-purified CCS shows the strongest 
intensity at a similar migration position, but expectedly contains many other proteins as well (data not shown). 
Likely due to the large glycosylation heterogeneity, captured EPO from CCS migrates in a very broad band. 
Nevertheless, the highest intensity is observed at a migration position close to the 37 kDa marker as well, albeit at 
Figure 3. EPO purity after affinity purification. From left to right: Eluate of the affinity purification from 
CCS (triplicate); Eluate without prior application of CCS (negative control); EPO standard in ascending order 
of amounts (1, 2 and 5 µg). The three different bands of each affinity purification of CCS were excised and 
subjected to a standard protein identification workflow (see Supporting Information Table S3).
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a slightly lower apparent molecular weight. The observation that the band for the EPO standard is more focused 
may be explained by purification steps which are likely to exclude proteoforms with extreme charge and/or size. 
The negative control proves that no significant amount of anti-EPO antibodies are eluted under the applied puri-
fication conditions, for example due to hydrolysis of the bead-antibody linkage. A proteomics analysis of the three 
bands after excision and in-gel digestion confirmed that all bands contain predominantly EPO (see Supporting 
Information Table S3). In Supporting Information Figure S1, a MALDI-TOF-MS spectrum of a blank elution 
after complete work-up is shown. The highest peak detected in this negative control is below the limit of quanti-
tation (LOQ) in the samples, proving that the affinity purification does not introduce significant contamination 
into the glycosylation analysis.
Furthermore, glycosylation profiles of the EPO standard were acquired before and after affinity purification. 
Figure 4 demonstrates only minimal quantitative differences proving that the applied affinity purification protocol 
does not significantly impact the EPO glycosylation profile. Notwithstanding, unusual glycoforms with reduced 
anti-EPO antibody affinity might escape the capturing step. These results were independently repeated using 
CGE–LIF as a readout (see Supporting Information Table S4). Additionally, we repeated the affinity purifica-
tion with monoclonal anti-EPO antibodies and obtained the same results (see Supporting Information Table S5). 
Since the specific epitope recognized by various commercially available antibodies may be different and may 
include glycans as epitopes, we recommend that a user of our method perform this test with their anti-EPO 
antibody of choice.
Recovery. The recovery of the affinity purification step was assessed with a BCA assay. The possibility to use the 
EPO standard for calibration instead of BSA increased our confidence in the obtained results. Nonetheless, due to 
its limited specificity the reported values should be understood as an estimation rather than exact values. A major 
improvement in recovery was afforded by switching the elution solvent from a 100 mM FA to a 100 mM HCl solu-
tion. This improved the recovery from 33 ± 4% (mean and standard deviation) to 54 ± 3% for the EPO standard 
and from 27 ± 6% to 48 ± 0.3% for the EPO purified from CCS. The change in elution solvent did not influence 
the glycan profile (see Supporting Information Figure S2). A minor improvement (58 ± 2% for the EPO purified 
from CCS) is afforded by not removing the excess bead buffer prior to binding to the beads (data not shown).
Optimization of the sample preparation and MALDI-TOF-MS analysis. Simplification of the 
denaturation procedure. Commonly, an incubation step with detergent, often SDS, at elevated temperatures is 
employed to denature the target protein prior to PNGaseF release. We have previously shown that the vacuum 
concentration of a protein from an acidic solution, which is part of the affinity purification protocol, can be suf-
ficient for denaturation23. Omitting the dedicated denaturation step reduces hands-on time, prevents addition of 
SDS which is known to interfere with MS performance and promotes repeatability. Importantly, a less complex 
sample preparation protocol is principally more robust. Moreover, sialic acids are well known to be thermolabile 
which is specifically crucial given their high abundance and key function in EPO. However, acknowledging that 
detergent denaturation is an established method in glycomics, we compared the glycosylation profiles with and 
without this dedicated denaturation step (see Fig. 5). No change in the qualitative and quantitative EPO glycan 
profile was observed and thus the technically preferable alternative of omitting the dedicated denaturation step 
was chosen as standard procedure. Additionally, the quality of the MALDI-TOF-MS profiles, as judged by the 
signal to noise ratios (S/N) for the 9 most abundant compositions and Man6P, was almost identical for both pro-
tocols (see Supporting Information Figure S3).
Figure 4. EPO composition selectivity during affinity purification. Profiles obtained with (grey) and without 
(black) affinity purification are highly similar. Only minor quantitative differences were observed.
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Other considerations. Increased sensitivity and the prevention of potential biases are ensured by driving the 
PGNaseF glycan release as close to completion as possible. Supporting Information Figure S4 demonstrates that 
complete release of N-glycans is achieved with 0.5 U of PNGaseF.
We have used 5 µg of EPO per analysis throughout the experiments reported in the manuscript, as this is 
already about ten times less than is usually applied for HILIC–FLD experiments31. This amount gives high qual-
ity spectra where many low abundant glycoforms can be detected. However, in a routine analysis, only the high 
abundant glycoforms may be of interest for bio-process controls and thus, it may be possible to achieve satisfac-
tory results with lower EPO amounts. We have tested a series of decreasing total EPO quantities and found that 
we still obtained satisfactory results for the 9 most abundant EPO glycans at 200 ng total protein level (Supporting 
Information Figure S5).
Assay performance. We also determined the precision of our method, by assessing the repeatability and 
intermediate precision of the whole workflow from CCS. The benefits and limitations of the information obtained 
on O-acetylation are briefly discussed. The accuracy was judged by comparison to a validated CGE–LIF method.
Our method has the advantage that it is significantly faster than conventional protocols7. Affinity captur-
ing takes about 2 h and another 2 h are usually spent drying. PNGaseF digestion is performed overnight. 
Derivatization is achieved in under 1.5 h. SPE takes approximately 1 h for a 96-well plate, but only a few minutes 
for a dozen of samples. While preparing the samples for MALDI-MS analysis can take between 30 to 60 min, the 
measurement itself is performed within seconds per sample on our instrumentation. Automated data analysis 
may be as fast as 30 min on a state-of-the art server. Thus, if CCS is available at midday, results may be obtained in 
the early afternoon of the next day. This is sufficiently fast with respect to the weeks a fermenter is usually oper-
ated, to obtain useful information on the production in progress.
Repeatability and intermediate precision. Repeatability and intermediate precision were assessed by measuring 
six replicates each of EPO including purification from CCS on two different days with the final method. Figure 6 
shows the N-glycosylation of the EPO purified from CCS measured in sextuplicate on two different days and 
analysed using the 9 most abundant EPO glycans and Man6P. Repeatability, expressed as coefficient of variation 
(CV), is between 2.3% and 6.2% (with one outlier at 9.4%) for the major analytes (above 10% relative abun-
dance). Minor glycans show CVs between 3.5% and 20.2%. No significant differences were observed between the 
means yielded at the different analysis days. For a comparison using all analytes (excluding O-acetylation) refer 
to Supporting information Table S1.
For the analysis of O-acetylation of sialic acids, the method yielded a good repeatability (RSD generally 
between 2% and 8%). However, the interday differences were significant, almost a factor of two in some instances. 
Accuracy was not assed as the CGE–LIF protocol relies on desialylation prior to glycan analysis. Details can be 
found in the Supporting Information in the section ‘Sialic acid O-acetylation analysis’.
Comparison of glycosylation data to a validated method. In order to judge the accuracy of the developed method, 
we compared the profiles of the EPO standard measured by our MALDI-TOF-MS method with data obtained 
by CGE–LIF analysis26. Because the resolution of the two approaches was very different, a summation of rel-
ative abundance was necessary to be able to compare the quantitative results. The CGE–LIF separation (after 
desialylation) is mainly based on antennarity. In the electropherograms, seven peaks were integrated belonging 
to bi-, tri- and tetra-antennary structures with no LacNAc repeats and tri- and tetra-antennary structures with 
one or two LacNAc repeats. While the MALDI-TOF-MS method distinguishes much more species based on the 
composition, it is not feasible to differentiate the isomeric structures sharing the same number of LacNAc units. 
Figure 5. Omission of an SDS denaturation step. Omitting the additional denaturation step, which uses heating 
to 60 °C for 10 min in 2% SDS, did not change the EPO N-glycan profile. This is beneficial, as SDS may interfere 
with PNGaseF release and MALDI analysis. Additionally, incubation at elevated temperatures bears the risk of 
desialylation.
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Thus, all areas of glycan species with an identical number of LacNAc units were summed for each method. The 
results shown in Fig. 7 are overall highly comparable. However, there is a preference for species with 3 LacNAc 
units and a negative bias for species with 5 LacNAc or 6 LacNAc units in the MALDI-TOF-MS analysis. While the 
different resolution of the CGE–LIF may offer a (partial) explanation, subtle differences in response factors of the 
MALDI-TOF-MS detection are also consistent with the differences.
Application to glycosylation analysis of a fermentation time course. In ten different CCS samples 
of a fermenter run, we found EPO glycosylation differences for most of the 9 most abundant EPO glycans. A 
Kruskal-Wallis test revealed differences in the relative abundances, for example, of H7N6F1S4 (p = 0.0076). We 
then compared each sample to the rest of the samples by a Mann-Whitney U test. The fermentation runs 1 and 7 
exhibited higher (run 1; 42.7 ± 1.3%) [mean ± standard deviation] vs. 39.8%(1.8%); p = 0.0001) and lower (run 
7 38.6%(2.0%) vs. 40.3%(1.9%); p = 0.045) H7N6F1S4 content compared to the other CCS samples. This demon-
strates that our method is powerful enough to also identify minor glycosylation differences in a time course of a 
fermentation.
Conclusions
We have developed a workflow which enables EPO N-glycosylation analysis in a fermentation time course. The 
workflow is faster than many existing protocols, automatable, and HT-compatible from sample preparation to 
quantitative data analysis. A high resolution also for low abundant EPO glycoforms was achieved. No obvious 
biases were incurred throughout the optimized protocol. However, it showed some limitations with respect to 
sialic acid O-acetylation.
We expect the method to be generally applicable. The general strategy (affinity purification, derivatization, 
purification, MALDI-MS analysis and automated data processing) has been used for glycans from many different 
Figure 6. Repeatability and intermediate precision of the MALDI-TOF-MS profiling method. Relative 
abundances of the 9 most abundant EPO glycans and Man6P were measured in sextuplicate on two different 
days. Major glycans showed a CV ≤6% and there were no significant differences between the profiles of both 
days.
Figure 7. Comparison of the MALDI-TOF-MS glycan profiles to CGE–LIF profiles. Relative abundance data 
was summed to comparable categories based on the number of LacNAc units.
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origins, such as plasma of humans and mice and different cells and cell lines (Chinese hamster ovary, human 
embryonic kidney and colorectal cancer derived; partially unpublished)21, 27, 32, 33. Additionally, we have not 
observed a glycoform bias of the anti-EPO antibody, despite the large diversity of glycans observed in terms of 
size and charge.
Our workflow resolves most of the important glycosylation features. In fact, quantitation of sialic acids, espe-
cially in combination with a distinction of N-acetyl- and N-glycolylneuramic acids, is lacking in some state-of-the 
art approaches26, 28. In contrast, the inability of our workflow to distinguish the position of the detected LacNAc 
units, especially to distinguish an additional antenna from a LacNAc repeat, is certainly a limitation. How much 
resolution is needed and what specific isomerism is important, in the end, needs to be judged on a case to case 
basis. In any case, our workflow delivers robust and high resolution results compared to established glycosylation 
analysis methods such as CGE–LIF.
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